Modified dose intensive R- CODOX-M/IVAC for HIV-associated burkitt (BL) (AMC 048) shows efficacy and tolerability, and predictive potential of IRF4/MUM1 expression

Benzer Materyaller

• AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma
  Yazar:: Noy, Ariela, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• FREQUENT EXPRESSION OF MUM1/IRF4 IN BURKITT LYMPHOMA
  Yazar:: Gualco, Gabriela, ve diğerleri
  Baskı/Yayın Bilgisi: (2009)
• HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era
  Yazar:: Rodrigo, J. A., ve diğerleri
  Baskı/Yayın Bilgisi: (2012)
• A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma
  Yazar:: Evens, A. M., ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma
  Yazar:: Evens, A. M., ve diğerleri
  Baskı/Yayın Bilgisi: (2014)